Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHIT1 | Q13231 | 10/20 | 0.44 |
| ▸ | CHIA | Q9BZP6 | 6/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | STS | P08842 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CHI3L1 | P36222 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18607749 | 0.91 | CHIT1 (0.48) | CHIT1CHIAKCNH2ATMALDH1A1 | |
| SCHEMBL18589463 | 0.91 | CHIT1 (0.48) | CHIT1CHIAKCNH2ATMALDH1A1 | |
| SCHEMBL18589334 | 0.91 | CHIT1 (0.48) | CHIT1CHIAKCNH2ATMALDH1A1 | |
| SCHEMBL18610038 | 0.91 | CHIT1 (0.48) | CHIT1CHIAKCNH2ATMALDH1A1 | |
| SCHEMBL26707702 | 0.90 | CHIT1 (0.45) | CHIT1CHIAKCNH2ATMALDH1A1 | |
| SCHEMBL26707461 | 0.89 | CHIT1 (0.41) | CHIT1CHIAKCNH2ATMALDH1A1 | |
| SCHEMBL26707523 | 0.88 | CHIT1 (0.50) | CHIT1CHIAKCNH2ATMALDH1A1 | |
| SCHEMBL18609870 | 0.88 | P2RX3 (0.41) | CHIT1CHIAATMALDH1A1STS | |
| SCHEMBL18607756 | 0.88 | P2RX3 (0.41) | CHIT1CHIAATMALDH1A1STS | |
| SCHEMBL18607754 | 0.88 | P2RX3 (0.41) | CHIT1CHIAATMALDH1A1STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4269400-B1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE SA (PL) | 2025-07-09 | — | — | EP | disclosed |
| US-20230348516-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-11-02 | — | — | US | disclosed |
| US-20230348516-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348516-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | CHI3L1, CHI3L2, CHIA | CHIT1 4/4885CHIA 3/4885KCNH2 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.